Pharming Group to report fourth quarter and full year 2024 financial results on March 13
27 Fevereiro 2025 - 4:00AM
UK Regulatory
Pharming Group to report fourth quarter and full year 2024
financial results on March 13
Leiden, the Netherlands, February 27,
2025: Pharming Group N.V. (“Pharming”) (Euronext
Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its
preliminary (unaudited) fourth quarter and full year 2024 financial
results, for the period ended December 31, on Thursday, March 13,
2025.
Pharming will host a presentation for analysts
and investors at 13:30 CET/08:30 am EDT on March 13, 2025.
To participate in the conference call, please
register in advance using the link below. Once registered, dial-in
information and a unique PIN will be provided, allowing access to
the call.
Conference call
registration:
Please note, the Company will only take questions from dial-in
attendees.
https://register.vevent.com/register/BI7d716758d12d4ad588b70fdbca665b6a
To watch the live webcast, please register in
advance using the link below.
Webcast registration:
https://edge.media-server.com/mmc/p/7qvoovac
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a
global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules and biologics. Pharming is headquartered
in Leiden, the Netherlands, and has employees around the globe who
serve patients in over 30 markets in North America, Europe, the
Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and
find us on LinkedIn.
For further public information,
contact:
Pharming Group, Leiden, the
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication,
Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
- Pharming Group to report 4Q_FY24 results_EN_27FEB25
Pharming Group NV (EU:PHARM)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Pharming Group NV (EU:PHARM)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025